News Releases

RNS Number : 5404B MaxCyte, Inc. 03 October 2022   MaxCyte, Inc.   (" MaxCyte " or the "Company")   TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN     Total Voting Rights Date: 3 October 2022 :   MaxCyte ( Nasdaq: MXCT; LSE: MXCT),   a leading commercial cell   -   engineering company focused on

Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation ® technology and ExPERT ™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies ROCKVILLE, Md., Sept. 28, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a

RNS Number : 0021B MaxCyte, Inc. 28 September 2022                                                                                                                                                                           MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to

Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities. ROCKVILLE, Md., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading commercial

RNS Number : 1410A MaxCyte, Inc. 21 September 2022       MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor    Expanded facilities illustrate MaxCyte's commitment to Montgomery County and the state of Maryland , building the life sciences community, and propelling

RNS Number : 6658Y MaxCyte, Inc. 08 September 2022   MaxCyte to Participate in Morgan Stanley 20 th Annual Global Healthcare Conference Rockville, MD , September 8, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling

ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development

RNS Number : 0087Y MaxCyte, Inc. 01 September 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 September 2022 :       MaxCyte (LSE: MXCT),   a leading commercial cell - engineering company focused on providing enabling platform technologies to

RNS Number : 6259V MaxCyte, Inc. 11 August 2022           MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022     ROCKVILLE, MD , August 11, 2022  -  MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a   leading commercial cell-engineering company focused on providing

RNS Number : 6262V MaxCyte, Inc. 11 August 2022           MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results   45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022   Raises 2022 Core Revenue Growth Guidance to Approximately 30%   ROCKVILLE, MD , August 11, 2022